https://www.selleckchem.com/pr....oducts/hpk1-in-2.htm
Two doses of propiverine ER (30 and 45 mg/d) are available for the treatment of overactive bladder (OA syndrome. We have explored factors associated with the initial dosing choice (allocation bias), the decision to adapt dosing (escalation bias) and how dosing relative to other factors affects treatment outcomes. Data from two non-interventional studies of 1335 and 745 OAB patients, respectively, receiving treatment with propiverine, were analyzed post-hoc. Multivariate analysis was applied to identify factors associated with dosing
Curtir
Comentario
Compartilhar
